Ema Kantorová

Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial

Daniel S. Reich, Douglas L. Arnold, Patrick Vermersch et al. · The Lancet Neurology · 2021 · 192 citations · Full text

Medicine, Neurology, Pharmacology +9

Hypothalamic damage in multiple sclerosis correlates with disease activity, disability, depression, and fatigue

Ema Kantorová, Hubert Poláček, Michal Bittšanský et al. · Neurological Research · 2017 · 46 citations · Full text

Life Sciences, Neurology, Neuroscience +16

Extensive Brain Pathologic Alterations Detected with 7.0-T MR Spectroscopic Imaging Associated with Disability in Multiple Sclerosis

Eva Hečková, Assunta Dal‐Bianco, Bernhard Strasser et al. · Radiology · 2022 · 37 citations

Medicine, Neurology, Radiology +17

Clinical correlations of proton magnetic resonance spectroscopy findings in acute phase after mild traumatic brain injury

Štefan Sivák, Michal Bittšanský, J. K. Grossmann et al. · Brain Injury · 2013 · 35 citations

Medicine, Neurology, Neuroscience +9

ApaI, BsmI and TaqI<i>VDR</i>gene polymorphisms in association with multiple sclerosis in Slovaks

Daniel Čierný, Jozef Michalík, Mária Škereňová et al. · Neurological Research · 2016 · 31 citations

Life Sciences, Genetics, Molecular Genetics +17